JAMM Therapeutics ^{For Profit}

JAMM Therapeutics is a drug discovery company developing small molecule modulators for the treatment of systemic lupus erythematosus (SLE). A family of cytokines known as type I IFNs exhibits antiviral, antiproliferative, and immunomodulatory functions. All type I IFNs function by attaching to the same receptor complex, which has the IFNAR1 and IFNAR2 subunits. IFNAR1 polyubiquitination, which instructs the internalized receptor for destruction in the lysosome, is one of the mechanisms regulating type I IFN activation. IFNAR1's K63-conjugated polyubiquitin chain can be disassembled by the cytoplasmic complex DUB, also known as BRISC (BRCC36 isopeptidase complex), which stabilizes IFNAR1 and encourages IFN-dependent reactions. Both in humans and mice, type I IFNs play a key role in the pathogenesis of SLE. When SLE is produced in BRISC-deficient mice, the mice show improved clinical functioning, reduced IFN responses, and protection against immunopathology linked to IFN.